By Lina carolina 
The global cancer burden is escalating at an alarming rate, with new cases more than doubling since 1990 and projected to surge by another 61 percent by 2050. This escalating crisis, particularly pronounced in low- and middle-income countries, underscores a critical paradox: nearly half of all cancer deaths worldwide are preventable through enhanced prevention strategies, earlier detection, and improved access to healthcare. A landmark analysis by the Global Burden of Disease Study (GBD) Cancer Collaborators, published in The Lancet, paints a stark picture of this unfolding global health emergency, demanding immediate and concerted action from governments, policymakers, and the international community.
A Steepening Trajectory: The Escalating Global Cancer Burden
The numbers are staggering. In 2023 alone, an estimated 18.5 million new cancer cases were diagnosed globally, a dramatic increase from the 8.9 million recorded in 1990. Concurrently, annual cancer deaths climbed by 74 percent over the same period, reaching 10.4 million in 2023, excluding non-melanoma skin cancers. This represents a significant jump from the 6 million deaths reported in 1990.
Looking ahead, the trajectory shows no signs of abatement. Projections indicate a further surge, with new cancer cases expected to reach 30.5 million annually by 2050. This represents an increase of 61 percent from current figures. Similarly, cancer deaths are forecast to rise by nearly 75 percent, reaching an alarming 18.6 million per year by mid-century. These increases are primarily attributed to two fundamental demographic shifts: the growing global population and the continuing aging of populations worldwide, as cancer incidence generally rises with age.
A particularly concerning aspect of this crisis is its disproportionate impact on resource-limited settings. The GBD analysis reveals that a significant portion of the growing cancer burden is concentrated in low- and middle-income countries (LMICs). It is projected that by 2050, more than half of all new cancer cases and nearly two-thirds of cancer deaths will occur in these regions, exacerbating existing health inequities.
The Shadow of Preventable Causes: A Call for Proactive Measures
Crucially, the GBD study highlights that a substantial proportion of this escalating cancer burden is linked to modifiable risk factors. Over 40 percent of all cancer deaths worldwide in 2023 were associated with 44 identifiable risk factors. These include prevalent issues such as tobacco use, poor dietary habits, high blood sugar levels, alcohol consumption, and environmental factors like air pollution. This statistic offers a glimmer of hope, emphasizing that a significant number of cancer deaths are not inevitable and can be averted through targeted prevention efforts.
"With four in 10 cancer deaths linked to established risk factors, including tobacco, poor diet, and high blood sugar, there are tremendous opportunities for countries to target these risk factors, potentially preventing cases of cancer and saving lives, alongside improving accurate and early diagnosis and treatment to support individuals who develop cancer," stated Dr. Theo Vos, a co-author of the study from the Institute for Health Metrics and Evaluation (IHME). "Reducing the burden of cancer across countries and worldwide demands both individual action and effective population-level approaches to reduce exposure to known risks."
A Shifting Landscape: Uneven Progress and Growing Disparities
While advancements in cancer treatment and awareness campaigns have been ongoing for decades, the GBD study reveals that global progress in reducing cancer death rates has been unevenly distributed. Although age-adjusted global cancer death rates have declined by 24 percent between 1990 and 2023, this positive trend has largely been confined to high- and upper-middle-income countries.
In stark contrast, low- and middle-income countries have witnessed an increase in both the absolute number of cancer deaths and, alarmingly, the age-standardized cancer incidence rates. Between 1990 and 2023, age-standardized cancer incidence rose by 24 percent in low-income countries and by 29 percent in lower-middle-income countries. This widening disparity underscores the urgent need to address systemic inequities in healthcare access and cancer control strategies.
The study also identified specific regional trends. For instance, Lebanon recorded the largest percentage increase in age-standardized cancer incidence and mortality rates for both sexes combined between 1990 and 2023. Conversely, the United Arab Emirates saw the greatest decline in age-standardized incidence, while Kazakhstan experienced the largest decrease in age-standardized death rates during the same period.
In terms of cancer types, breast cancer emerged as the most commonly diagnosed cancer globally in 2023 for both sexes combined. Tracheal, bronchus, and lung (TBL) cancer, however, remained the leading cause of cancer-related deaths worldwide.
The Imperative of Prevention: Targeting Modifiable Risk Factors
The identification of modifiable risk factors as a driver of over 40 percent of cancer deaths presents a critical pathway for intervention. Behavioral risk factors, in particular, accounted for the largest share of cancer deaths across all income levels in 2023. Tobacco use alone was responsible for an estimated 21 percent of global cancer deaths. It was the leading risk factor in most income groups, with the exception of low-income countries, where unsafe sex was identified as the primary risk factor, contributing to 12.5 percent of cancer deaths.
The analysis also revealed gender-specific patterns in risk factor attribution. In 2023, 46 percent of cancer deaths in men were linked to factors such as tobacco use, unhealthy diets, high alcohol consumption, occupational hazards, and air pollution. For women, 36 percent of cancer deaths were associated with modifiable risks, with tobacco, unsafe sex, unhealthy diets, obesity, and high blood sugar being the most significant contributors.
"The rise of cancer in LMICs is an impending disaster," warned Dr. Meghnath Dhimal from the Nepal Health Research Council, a co-author of the study. "There are cost-effective interventions for cancer in countries at all stages of development. These cancer burden estimates can help broaden the discussion around the importance of cancer and other non-communicable diseases in the global health agenda. To control the growth of non-communicable diseases including cancer in LMICs, an interdisciplinary approach for evidence generation and multi-sectoral collaboration and coordination for implementation are urgently needed."
The UN Sustainable Development Goals: A Widening Gap
The findings from the GBD study also highlight a significant challenge in achieving global health targets. The projected increase in cancer cases and deaths between 2024 and 2050 falls considerably short of the United Nations Sustainable Development Goal (SDG) 3.4, which aims to reduce premature deaths from non-communicable diseases, including cancer, by one-third by 2030. This shortfall underscores the urgent need for accelerated action and increased investment in cancer control programs worldwide.
Expert Calls for Global Action and Equitable Access
Leading researchers involved in the GBD study have issued strong calls for intensified global action. Dr. Lisa Force from IHME, the lead author, emphasized the critical need for prioritizing cancer control policies and implementation in global health agendas. "Despite the clear need for action, cancer control policies and implementation remain underprioritized in global health, and there is insufficient funding to address this challenge in many settings," she stated.
Dr. Force further stressed the importance of addressing disparities in healthcare delivery. "Ensuring equitable cancer outcomes globally will require greater efforts to reduce disparities in health service delivery such as access to accurate and timely diagnosis, and quality treatment and supportive care."
The study’s methodology involved synthesizing data from a comprehensive array of sources, including population-based cancer registries, vital registration systems, and interviews with family members or caregivers of deceased patients. This rigorous approach provides updated global, regional, and national estimates for 47 cancer types and 44 attributable risk factors across 204 countries and territories, spanning from 1990 to 2023. The projections extend to 2050, offering a crucial forward-looking perspective.
Addressing Data Gaps and Future Challenges
The authors of the GBD study acknowledge certain limitations that may influence their estimates. The reliability of the data is inherently tied to the availability of high-quality cancer registries, which remain scarce in many resource-limited countries. Furthermore, the current estimates do not fully account for the impact of certain infectious diseases known to increase cancer risk in specific regions, such as Helicobacter Pylori and Schistosoma haematobium. The projections also do not incorporate the potential long-term effects of the COVID-19 pandemic, recent geopolitical conflicts, or future medical breakthroughs, which could significantly alter cancer trends.
In a commentary accompanying the study, Dr. Qingwei Luo and Dr. David P Smith from The University of Sydney and Cancer Council NSW, who were not involved in the research, echoed the call for decisive action. They stated, "To ensure meaningful progress in reducing the global cancer burden, it is imperative that governments prioritize funding, strengthen health systems, reduce inequalities, and invest in robust cancer control initiatives and research on prevention, intervention, and implementation — because the future of cancer control depends on decisive, collective action today."
The GBD study, funded by prominent organizations including the Gates Foundation, St Jude Children’s Research Hospital, and St Baldrick’s Foundation, provides a critical evidence base for policymakers. "These new estimates and forecasts can support governments and the global health community in developing data informed policies and actions to improve cancer control and outcomes around the world," Dr. Force concluded. "They can also support tracking of progress towards global and regional cancer targets." The call for enhanced cancer surveillance systems and more robust data collection, particularly in LMICs, remains paramount for both local and global understanding and management of the evolving cancer epidemic.
